Mutabilis is a biopharmaceutical company developing novel chemical entities, from biological targets to the end of Phase I, to treat MDR Gram-negative bacterial infections. Mutabilis’ team has a unique expertise in diazabicyclooctane chemistry and its applications in the discovery of novel antibacterials and beta-lactamase inhibitors. With outstanding stability to serine- and metallo-beta-lactamases hydrolysis, diazabicycloo...
Mutabilis is a biopharmaceutical company developing novel chemical entities, from biological targets to the end of Phase I, to treat MDR Gram-negative bacterial infections. Mutabilis’ team has a unique expertise in diazabicyclooctane chemistry and its applications in the discovery of novel antibacterials and beta-lactamase inhibitors. With outstanding stability to serine- and metallo-beta-lactamases hydrolysis, diazabicyclooctane derivatives are particularly promising to address the most difficult infections, namely those that are resistant to carbapenems.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.